Metabolic characterization of the major human small intestinal cytochrome P450S

Drug Metabolism and Disposition

Volumn 29, Issue 3, 2001, Pages 347-352

  Obach, R S ^a   Zhang, Q Y ^a   Dunbar, D ^a   Kaminsky, L S ^a  

^a WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DICLOFENAC; MEPHENYTOIN; OXYGENASE; SULFAPHENAZOLE; TESTOSTERONE; TICLOPIDINE;

ARTICLE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; SMALL INTESTINE;

ADULT; AGED; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; ENTEROCYTES; FEMALE; HUMANS; HYDROXYLATION; IMMUNOBLOTTING; INTESTINE, SMALL; ISOENZYMES; KINETICS; MALE; MEPHENYTOIN; MICROSOMES; MIDDLE AGED; MIXED FUNCTION OXYGENASES; REGRESSION ANALYSIS; SULFAPHENAZOLE; TESTOSTERONE; TICLOPIDINE;

EID: 0035118551     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Grapefruit juice-drug interactions
2. Ethyl acetate extraction procedure and isocratic high-performance liquid chromatographic assay for testosterone metabolites in cell microsomes
3. Hepatic metabolism of diclofenac: Role of human CYP in the minor oxidative pathways
4. Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa
5. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: Contribution of several CYP isoforms
6. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase
7. Steroid metabolism by rabbit olfactory-specific P450 2G1
8. Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19
9. Development of a non-high pressure liquid chromatography assay to determine testosterone hydroxylase (CYP3A) activity in human liver microsomes
10. A new genetic defect in human CYP2C19: Mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin
11. I values and impact of CYP3A5 expression
12. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
13. Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities
14. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin
15. Novel 2-point linked mutations in the 5′-flanking region of human CYP2C18
16. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes
17. In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6
18. Expression of CYP2A genes in human liver and extrahepatic tissues
19. Linkage of mutant alleles of CYP2C18 and CYP2C19 in a Japanese population
20. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
21. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide. S-mephenytoin, and omeprazole hydroxylations
22. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression
23. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines
24. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6
25. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations
26. Cytochrome P4502C9: An enzyme of major importance in human drug metabolism
27. Comparison of the substrate specificities of human liver cytochrome p450s 2C9 and 2C18: Application to the design of a specific substrate of CYP2C18
28. Synthesis and quantitative structure-activity relationships of diclofenac analogues
29. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression
30. The carbon monoxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
31. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity
32. Characterization of six in vitro reactions mediated by human cytochrome P450: Application to the testing of cytochrome P450-directed antibodies
33. CYP2C9 lle359 and Leu359 variants: Enzyme kinetic study with seven substrates
34. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac
35. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
36. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes
37. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach
38. The barrier function of CYP3A4 and P-glycoprotein in the small bowel
39. Steroid hormone hydroxylase specificities of eleven eDNA-expressed human cytochrome P450s
40. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes
41. Characterization of human small intestinal cytochromes P-450